Vaccine Therapy in Treating Patients With Metastatic Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

February 29, 1996

Primary Completion Date

August 31, 2000

Conditions
Melanoma (Skin)
Interventions
BIOLOGICAL

QS21

vaccine adjuvant

BIOLOGICAL

IFA (incomplete Freund's adjuvant)

Peptides emulsified in IFA.

BIOLOGICAL

p946

This a nonamer peptide YLEPGPVTA from Gp100, used as a melanoma vaccine antigen.

BIOLOGICAL

p946/tet-p

This peptide is a longer version of p946 (gp100 \[280-288\]) sythesized colinearly with the tetanus helper peptide (Tet-p)

BIOLOGICAL

Tet-p

modified form of the p2 peptide from tetanus toxoid, used as nonspecific epitope for helper T cells.

Trial Locations (1)

22908

Cancer Center, University of Virginia HSC, Charlottesville

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Virginia

OTHER

NCT00003224 - Vaccine Therapy in Treating Patients With Metastatic Melanoma | Biotech Hunter | Biotech Hunter